Medical Treatment for High Cortisol Levels (Hypercortisolism)
For patients with hypercortisolism, adrenal steroidogenesis inhibitors are the first-line medical therapy, with ketoconazole, osilodrostat, or metyrapone as the preferred initial agents for most patients. 1
Treatment Selection Algorithm
For Mild Disease (No Visible Tumor on MRI)
- Start with: Ketoconazole, osilodrostat, or metyrapone 1
- Cabergoline is an alternative but less effective with slower onset 1
- Response timeline: Osilodrostat/metyrapone work within hours; ketoconazole within days 1
For Mild-to-Moderate Disease (With Residual Tumor)
- Prefer: Cabergoline or pasireotide for potential tumor shrinkage 1
- Critical caveat: Pasireotide causes high rates of hyperglycemia—avoid in patients with diabetes or prediabetes 1
For Severe Disease (Life-Threatening Hypercortisolism)
Rapid cortisol normalization is the primary goal to prevent mortality. 1
- First-line: Osilodrostat or metyrapone (response within hours) 1
- Alternative: Ketoconazole (response within days) 1
- If hospitalized and unable to take oral medications: Etomidate 1
- If medical therapy fails: Combination steroidogenesis inhibitors or bilateral adrenalectomy 1
Specific Drug Considerations
Osilodrostat
- Highest efficacy among steroidogenesis inhibitors with 67.9% achieving cortisol control 2
- FDA-approved in the United States (only approved steroidogenesis inhibitor for Cushing's disease) 1
- Twice-daily dosing with rapid onset 1
- Monitor for adrenal insufficiency and androgen effects 1
Ketoconazole
- 64.3% achieve UFC normalization 1
- Major limitation: Hepatotoxicity in 10-20% (usually mild, reversible) 1, 3
- Monitor liver function tests weekly initially, then regularly 3
- Causes hypogonadism in men (gynecomastia, decreased libido) 1
- Not FDA-approved for Cushing's in the US but widely used off-label 1
Metyrapone
- Rapid onset (hours) 1
- Safe in pregnancy (only option with some safety data) 1, 3
- Side effects: Hirsutism, acne (from androgen accumulation), hypokalemia 3
- Critical monitoring issue: Causes falsely elevated cortisol on immunoassays—use liquid chromatography-mass spectrometry 3
Mifepristone (Glucocorticoid Receptor Antagonist)
- Only use with extensive experience in Cushing's disease 1
- Improves hyperglycemia and weight gain specifically 1
- Major limitation: Cannot monitor cortisol levels for efficacy or adrenal insufficiency 1
- Worsens hypokalemia 1
- Long half-life complicates management of adrenal insufficiency 1
Combination Therapy
When monotherapy fails:
- Most common: Ketoconazole + metyrapone (maximizes adrenal blockade) 1
- Alternative: Steroidogenesis inhibitor + tumor-targeting agent (e.g., ketoconazole + cabergoline) 1
- Monitor for: QTc prolongation with combinations 1
Special Populations
Pregnancy
- Only option: Metyrapone with precautions 1
- Target higher cortisol levels (1.5 × upper limit of normal) 1
Psychiatric History
- Avoid cabergoline in bipolar disorder or impulse control disorders 1
Young Women Desiring Pregnancy
- Prefer cabergoline (dopamine agonist with better reproductive profile) 1
Monitoring Requirements
- Urinary free cortisol (UFC): Primary monitoring tool (except with mifepristone) 1
- Morning cortisol and late-night salivary cortisol: Alternative markers 1
- Clinical parameters: Weight, blood pressure, glucose, symptoms 1
- Drug-specific: Liver function (ketoconazole), potassium (metyrapone, mifepristone), androgens (osilodrostat) 1, 3
Critical Pitfalls to Avoid
- Under-dosing ketoconazole due to hepatotoxicity fears—mild LFT elevations (≤3× ULN) don't require discontinuation 1
- Missing adrenal insufficiency with aggressive treatment—monitor closely during dose titration 1
- Using standard cortisol assays with metyrapone—11-deoxycortisol cross-reacts, falsely elevating results 3
- Attempting mifepristone without expertise—no reliable monitoring for cortisol levels or adrenal insufficiency 1
- Ignoring hypokalemia—occurs in 30% with ketoconazole and worsens with mifepristone 4, 1